Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) Non-Current Receivables (2016 - 2025)

Marimed has reported Non-Current Receivables over the past 11 years, most recently at $827000.0 for Q2 2025.

  • Quarterly Non-Current Receivables rose 39.46% to $827000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $827000.0 through Jun 2025, up 39.46% year-over-year, with the annual reading at $556000.0 for FY2024, 11.75% down from the prior year.
  • Non-Current Receivables was $827000.0 for Q2 2025 at Marimed, up from $556000.0 in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $8.5 million in Q2 2023 and troughed at $556000.0 in Q4 2024.
  • The 5-year median for Non-Current Receivables is $814000.0 (2023), against an average of $1.4 million.
  • Year-over-year, Non-Current Receivables surged 1047.49% in 2023 and then tumbled 92.99% in 2024.
  • A 5-year view of Non-Current Receivables shows it stood at $1.7 million in 2021, then plummeted by 58.05% to $704000.0 in 2022, then fell by 10.51% to $630000.0 in 2023, then fell by 11.75% to $556000.0 in 2024, then surged by 48.74% to $827000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Non-Current Receivables are $827000.0 (Q2 2025), $556000.0 (Q4 2024), and $814000.0 (Q3 2024).